Keywords: eu, commission, role, speedier, approvals, pis, after

EU Commission role in speedier approvals and PIs after enlargement: Liikanen

Article | 08 July 2002

The European Commission recognizes that European Union member states'national reimbursement and pricing systems frequently constitute a barrier to new medicines ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bayer

Go to company listing

Related Drugs

Aspirin

Bayer

Go to drug listing